Chemotherapy in Patient with Colon Cancer After Renal Transplantation: A Case Report with Literature Review

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Feb 1

PMID 29384845

Citations 3

Authors

Wentong Fang

Affiliations

Soon will be listed here.

Abstract

Rationale: Experience of pharmacotherapy in posttransplantation colorectal cancer (CRC) patients is inadequate.

Patient Concerns: A Chinese man had right renal transplantation and began immunosuppressive treatment at the age of 31 in 2009. He was diagnosed with colon cancer and underwent anterior resection in 2014. He was diagnosed with metastatic colon carcinoma by abdomen computed tomography (CT) and positron emission tomography-computed tomography in April 2017.

Diagnosis: Metastatic colon carcinoma in posttransplantation patient.

Interventions: Three cycles of FLOFOX (5-fluorouracil and leucovorin and oxaliplatin) chemotherapy were given since April 2017.

Outcomes: Plasma concentrations of immunosuppressant and kidney function were within normal during the chemotherapy. Abdomen CT revealed the progress of colon cancer at the end of the third course of chemotherapy.

Lessons: A few cases about monochemotherapy of posttransplantation CRC have been reported, whereas experience of doublet chemotherapy was currently unavailable. We shared the experience of FOLFOX in a patient with posttransplantation colon cancer. Neither of incompatibility with immunosuppressant nor serious adverse drug reaction was observed. It provides evidence for the pharmacotherapy of posttransplantation CRC.

Citing Articles

Transplanted kidney loss during colorectal cancer chemotherapy: A case report.

Pospiech M, Kolonko A, Nieszporek T, Kozak S, Kozaczka A, Karkoszka H World J Clin Cases. 2022; 10(19):6647-6655.

PMID: 35979324 PMC: 9294886. DOI: 10.12998/wjcc.v10.i19.6647.

Effective chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a patient with metastatic colon cancer following renal transplantation: a case report.

Bellyei S, Boronkai A, Pozsgai E, Fodor D, Mangel L J Med Case Rep. 2021; 15(1):125.

PMID: 33741057 PMC: 7980581. DOI: 10.1186/s13256-021-02702-y.

Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients.

Fu Y, Liao C, Cui K, Liu X, Fang W Ther Adv Med Oncol. 2019; 11:1758835919876196.

PMID: 31579127 PMC: 6759705. DOI: 10.1177/1758835919876196.

References

Trivedi M, Agrawal S, Muscato M, Metzler M, Marshall J . High grade, synchronous colon cancers after renal transplantation: were immunosuppressive drugs to blame?. Am J Gastroenterol. 1999; 94(11):3359-61. DOI: 10.1111/j.1572-0241.1999.01553.x. View

Vincenzi B, Santini D, Galluzzo S, Russo A, Fulfaro F, Silletta M . Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res. 2008; 14(13):4219-24. DOI: 10.1158/1078-0432.CCR-08-0077. View

Koopman M, Antonini N, Douma J, Wals J, Honkoop A, Erdkamp F . Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007; 370(9582):135-142. DOI: 10.1016/S0140-6736(07)61086-1. View

Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P . Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol. 2010; 22(5):1141-1146. DOI: 10.1093/annonc/mdq550. View

Hurwitz H, Tebbutt N, Kabbinavar F, Giantonio B, Guan Z, Mitchell L . Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013; 18(9):1004-12. PMC: 3780632. DOI: 10.1634/theoncologist.2013-0107. View

Cao Y, Liu L, Liao C, Tan A, Gao F . Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol. 2009; 66(1):37-42. DOI: 10.1007/s00280-009-1131-5. View

Vickers M, Karapetis C, Tu D, OCallaghan C, Price T, Tebbutt N . Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann Oncol. 2012; 24(4):953-60. DOI: 10.1093/annonc/mds577. View

Seymour M, Maughan T, Ledermann J, Topham C, James R, Gwyther S . Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007; 370(9582):143-152. DOI: 10.1016/S0140-6736(07)61087-3. View

Liu H, Liang X, Li Y, Feng Y, Liu D, Wang W . Treatment of advanced rectal cancer after renal transplantation. World J Gastroenterol. 2011; 17(15):2058-60. PMC: 3082763. DOI: 10.3748/wjg.v17.i15.2058. View

10.

Zhu X, Wu S, Dahut W, Parikh C . Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007; 49(2):186-93. DOI: 10.1053/j.ajkd.2006.11.039. View

11.

Kim J, Ju M, Kim M, Kim N, Sohn S, Kim S . Clinical characteristics and treatment outcomes of colorectal cancer in renal transplant recipients in Korea. Yonsei Med J. 2011; 52(3):454-62. PMC: 3101048. DOI: 10.3349/ymj.2011.52.3.454. View

12.

Pendon-Ruiz de Mier V, Navarro Cabello M, Martinez Vaquera S, Lopez-Andreu M, Aguera Morales M, Rodriguez-Benot A . Incidence and Long-Term Prognosis of Cancer After Kidney Transplantation. Transplant Proc. 2015; 47(9):2618-21. DOI: 10.1016/j.transproceed.2015.08.043. View

13.

Musri F, Mutlu H, Karakurt Eryilmaz M, Kivrak Salim D, Coskun H . Experience of bevacizumab in a patient with colorectal cancer after renal transplantation. J Cancer Res Ther. 2016; 11(4):1018-20. DOI: 10.4103/0973-1482.168996. View

14.

Schwartzberg L, Rivera F, Karthaus M, Fasola G, Canon J, Hecht J . PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic.... J Clin Oncol. 2014; 32(21):2240-7. DOI: 10.1200/JCO.2013.53.2473. View

15.

Saidi R, Dudrick P, Goldman M . Colorectal cancer after renal transplantation. Transplant Proc. 2003; 35(4):1410-2. DOI: 10.1016/s0041-1345(03)00478-0. View

16.

Schrag D, Chung K, Flombaum C, Saltz L . Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst. 2005; 97(16):1221-4. DOI: 10.1093/jnci/dji242. View

17.

Papaconstantinou H, Sklow B, Hanaway M, Gross T, Beebe T, Trofe J . Characteristics and survival patterns of solid organ transplant patients developing de novo colon and rectal cancer. Dis Colon Rectum. 2004; 47(11):1898-903. DOI: 10.1007/s10350-004-0674-0. View